Iovance Biotherapeutics
IOVA
12.92
-0.05
-0.35%
Iovance Biotherapeutics
US · IOVA
#1864 by market cap
Listed 1970
12.92
-0.05
-0.35%
Live - 5344 symbols - heartbeat 569s ago
· 2026-10-08 07:39
Pre-market
12.81
-0.81%
After-hours
12.88
-0.27%
Overnight
12.94
+0.19%
- Market cap
- 5.85B
- P/E (TTM)i
- -18.72
- P/Bi
- 7.95
- EPSi
- -1.09
- Div yieldi
- 0.00%
- 52W posi
- 82%
Reader sentiment
Are you bullish or bearish on IOVA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.4 percentage points.
Institutional ownership
- Held by institutions
- 64.18% +0.37pp
- Institutions
- 332 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund37.62%
Hedge Fund12.23%
Individual/Insider6.56%
VC/PE Fund6.39%
Public Company4.18%
Private Company2.79%
Insurance Company0.63%
Government Pension Fund0.30%
Other29.27%
Top holders as of 2026-06-30
BlackRock
8.16% · 36.96M sh
MHR Fund Management LLC
6.39% · 28.97M sh
Wayne Rothbaum
6.20% · 28.07M sh
State Street Global Advisors
5.40% · 24.48M sh
Vanguard Capital Management, LLC
4.58% · 20.75M sh
Two Sigma Investments, LP
4.20% · 19.01M sh
Vanguard Portfolio Management, LLC
3.18% · 14.39M sh
Geode Capital Management, LLC
2.28% · 10.32M sh
Millennium Management LLC
1.88% · 8.53M sh
Dimensional Fund Advisors
1.43% · 6.46M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 32 buys · 18 sells
| Name | Role | Stake |
|---|---|---|
| Wayne Rothbaum | Independent Director | 6.20% |
| Frederick Vogt | Interim CEO, President, General Counsel & Corporate Secretary | 0.13% |
| Raj Puri | Executive VP of Regulatory Strategy & Translational Medicine | 0.06% |
| Daniel Kirby | Chief Commercial Officer | 0.03% |
| Igor Bilinsky | Chief Operating Officer | 0.03% |
| Michael Weiser | Independent Director | 0.03% |
| Friedrich Graf Finckenstein | Chief Medical Officer | 0.03% |
| Matthew Rosinack | Interim Principal Financial Officer & Principal Accounting Officer | 0.02% |
| Iain Dukes | Independent Chairperson | 0.01% |
| Corleen Roche | Chief Financial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Noah Berkowitz | Chief Medical Officer | Other Derivative Acquisition | +135,000 | $14.82 |
| 2026-09-29 | Noah Berkowitz | Chief Medical Officer | Other Derivative Acquisition | +180,000 | -- |
| 2026-09-07 | Igor Bilinsky | Chief Operating Officer | Derivative Exercise and Sale | -3,976 | $8.70 |
| 2026-09-07 | Igor Bilinsky | Chief Operating Officer | Derivative Exercise and Retained | +3,837 | -- |
| 2026-09-07 | Frederick Vogt | Interim CEO, President, General Counsel & Corporate Secretary | Derivative Exercise and Sale | -6,638 | $8.70 |
| 2026-09-07 | Frederick Vogt | Interim CEO, President, General Counsel & Corporate Secretary | Derivative Exercise and Retained | +8,988 | -- |
| 2026-09-07 | Raj Puri | Executive VP of Regulatory Strategy & Translational Medicine | Derivative Exercise and Sale | -4,478 | $8.70 |
| 2026-09-07 | Raj Puri | Executive VP of Regulatory Strategy & Translational Medicine | Derivative Exercise and Retained | +5,288 | -- |
| 2026-08-31 | Igor Bilinsky | Chief Operating Officer | Derivative Exercise and Sale | -4,472 | $8.28 |
| 2026-08-31 | Igor Bilinsky | Chief Operating Officer | Derivative Exercise and Retained | +4,317 | -- |
| 2026-08-31 | Frederick Vogt | Interim CEO, President, General Counsel & Corporate Secretary | Derivative Exercise and Sale | -17,702 | $8.28 |
| 2026-08-31 | Frederick Vogt | Interim CEO, President, General Counsel & Corporate Secretary | Derivative Exercise and Retained | +23,967 | -- |
| 2026-08-31 | Raj Puri | Executive VP of Regulatory Strategy & Translational Medicine | Derivative Exercise and Sale | -2,508 | $8.28 |
| 2026-08-31 | Raj Puri | Executive VP of Regulatory Strategy & Translational Medicine | Derivative Exercise and Retained | +2,962 | -- |
| 2026-08-09 | Daniel Kirby | Chief Commercial Officer | Derivative Exercise and Sale | -2,436 | $6.40 |
| 2026-08-09 | Daniel Kirby | Chief Commercial Officer | Derivative Exercise and Retained | +7,565 | -- |
| 2026-08-05 | Corleen Roche | Chief Financial Officer | Derivative Exercise and Sale | -21,238 | $6.21 |
| 2026-08-05 | Corleen Roche | Chief Financial Officer | Derivative Exercise and Retained | +28,757 | -- |
| 2026-06-15 | Michael Weiser | Independent Director | Other Derivative Acquisition | +90,316 | -- |
| 2026-06-15 | Ryan Maynard | Independent Director | Other Derivative Acquisition | +90,316 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:39:53 · For reference only, not investment advice and not tailored to your situation.